NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-192-2008-1-PCT-02 Optimization Of Expression Of Multimeric Proteins PCT PCT PCT/US2009/043481 Expired
NIEHS E-170-2000-0-US-05 A Non-Steroidal Anti-Inflammatory Drug Related Gene (NAG-1) And Secreted Protein That Has Anti-Tumorigenic Properties US DIV 12/463,666 Abandoned
NCI E-197-2009-0-US-01 TREM-like Transcript-1 Protects Against Inflammation-associated Hemorrhage By Facilitating Platelet Aggregation In Mice And Humans US 61/177,242 Abandoned
NCI E-285-2006-2-US-02 Differential Gene Expression In Physiological And Pathological Angiogenesis US National Stage 12/514,297 Abandoned
NIDCR E-118-2009-0-US-01 Compound Deletions Of TGF-beta Receptor I And Pten Genes Cause Head And Neck Squamous Cell Carcinoma US 61/176,723 Abandoned
NIEHS E-156-2009-0-US-01 Composition And Methods for the Prevention and Treatment of Lupus Nephritis Using Anti-dsDNA Germline Antibodies US 61/176,615 Abandoned
NIAID E-029-2007-0-US-03 Recombinant Virus with Diminished Latency and Methods of Using Same US National Stage 12/514,011 10166285 Issued PDF
NCI E-071-1992-2-JP-12 METHOD OF ELIMINATING INHIBITORY/INSTABILITY REGIONS FROM mRNA JP DIV 2009-112524 Expired
NCI E-159-2009-0-US-01 Mutation Of Critcal Lysines In The LAT Adapter Molecular Leads To Enhance T Cell Signalling US 61/176,231 Abandoned
NIDCR E-185-2009-0-US-01 Use Of A Hybrid Adenoretroviral Vector To Prevent Radiation-induced Oral Mucositis Following Gene Transfer To Salivary Glands US 61/176,210 Abandoned
NIAID E-189-2008-2-EP-04 LEISHMANIA VACCINE USING SAND FLY SALIVARY IMMUNOGEN EP National Stage 09743563.0 Issued
NIAID E-189-2008-2-MX-07 LEISHMANIA VACCINE USING SAND FLY SALIVARY IMMUNOGEN MX National Stage MX/a/2010/012069 Issued
NIAID E-189-2008-2-US-03 LEISHMANIA VACCINE USING SAND FLY SALIVARY IMMUNOGEN US National Stage 12/436,398 8603808 Issued PDF
NIAID E-189-2008-2-TN-02 Leishmania Vaccine Using Sand Fly Salivary Immunogen TN National Stage 2010/0500 Issued
NCI E-256-2006-0-SG-10 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs SG National Stage 200903196-4 Abandoned
NCI E-256-2006-0-NZ-09 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs NZ National Stage 576769 Abandoned
NCI E-014-2007-0-NZ-14 SELF-ASSEMBLING NANOPARTICLES COMPOSED OF TRANSMEMBRANE PEPTIDES AND THEIR APPLICATION FOR SPECIFIC INTRA-TUMOR DELIVERY OF ANTI-CANCER DRUGS NZ National Stage 576467 Abandoned
NCI E-256-2006-0-ZA-12 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs ZA National Stage 2009/03125 Abandoned
NIAID E-189-2008-2-PCT-01 LEISHMANIA VACCINE USING SAND FLY SALIVARY IMMUNOGEN PCT PCT COMB PCT/US2009/042980 Expired
NCI E-072-2008-0-PCT-02 HIV Immunogen and Method of Making and Using Same PCT PCT PCT/US2009/043054 Expired
NHLBI E-173-2009-0-US-01 Device And Method For Sterile Removal Of Sample From Cryopreserved Bag US 61/175,131 Abandoned
NCI E-050-2007-2-JP-05 MICRORNA EXPRESSION SIGNATURE FOR PREDICTING SURVIVAL AND METASTASES IN HEPATOCELLULAR CARCINOMA JP National Stage 2009-535366 Abandoned
NCI E-050-2007-2-US-06 MicroRNA Expression Signature For Predicting Survival And Metastases in Hepatocellular Carcinoma US National Stage 12/513,219 8252538 Abandoned PDF
NCI E-160-2006-0-US-04 Azonafide Derived Tumor and Cancer Targeting Compounds US National Stage 12/441,029 8008316 Issued PDF
NCI E-256-2006-0-JP-08 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs JP National Stage 2009-535502 Abandoned
NCI E-059-1997-0-US-19 RECOMBINANT Antibodies And IMMUNO-CONJUGATES TARGETED TO CD-22 BEARING CELLS AND TUMORS US DIV 12/433,737 9592304 Abandoned PDF
NCI E-123-2008-0-PCT-02 Asparagine Substitution To Prevent Deamidation Of IL-15Asparagine Substitution To Prevent Deamidation Of IL-15Asparagine PCT PCT PCT/US2009/042355 Expired
NINDS E-160-2009-1-EP-01 Quinone derivative 2, 3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis EP ORD 09006030.2 Abandoned
NCI E-170-2009-0-US-01 Methods Of Preparing Lymphocytes That Express Interleukin-12 And Their Use In The Treatment Of Cancer US 61/174,046 Abandoned
NINDS E-160-2009-0-US-01 Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis US 61/174,170 Abandoned
NCI E-183-2009-0-US-01 The Natural Product Schweinfurthin A And Synthetic Schweinfurthin Analogs Specifically Inhibit NF1-null Cells And May Be Useful As A Therapy For Neurofibromatosis Type 1. US 61/174,338 Abandoned
NCI E-014-2007-0-SG-16 SMOOTHENED POLYPEPTIDES AND METHODS OF USE SG National Stage 200903030-5 Abandoned
NCI E-014-2007-0-ID-08 SMOOTHENED POLYPEPTIDES AND METHODS OF USE ID National Stage W-00200901121 Abandoned
NCI E-014-2007-0-KR-11 SMOOTHENED POLYPEPTIDES AND METHODS OF USE KR National Stage 10-2009-7008873 Abandoned
NCI E-152-2007-0-US-11 Non-M Non-O HiV Strains, Fragments And Uses US DIV 12/385,973 8227185 Expired PDF
NCI E-304-2006-0-US-03 Modified T Cell Receptors and Related Materials and Methods. US National Stage 12/443,111 8088379 Issued PDF
NCI E-014-2007-0-PH-15 SMOOTHENED POLYPEPTIDES AND METHODS OF USE PH National Stage 1-2009-500816 Abandoned
NCI E-014-2007-0-JP-10 SMOOTHENED POLYPEPTIDES AND METHODS OF USE JP National Stage 2009-534941 Abandoned
NCI E-324-2001-2-US-03 Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with Neuroblastoma US National Stage 11/572,667 8283122 Abandoned PDF
NCI E-014-2007-0-ZA-18 SMOOTHENED POLYPEPTIDES AND METHODS OF USE ZA National Stage 2009/02894 Abandoned
NCI E-116-2003-0-US-04 Immunogenic Peptides And Peptide Derivatives For Prostate And Breast Cancer Treatment US DIV 12/430,837 8043623 Expired PDF
CC E-066-2010-0-US-04 SYSTEM AND METHOD FOR FUSING REAL-TIME ULTRASOUND IMAGES WITH PRE-ACQUIRED MEDICAL IMAGES US National Stage 12/516,407 8731264 Issued PDF
NCI E-050-2007-2-ES-09 MicroRNA Expression Signature for Predicting Survival and Metastases in Hepatocellular Carcinoma (miR-207, miR-219, miR-30c,miR-124a) ES EP 07867402.5 Abandoned
NCI E-050-2007-2-DE-08 MicroRNA Expression Signature for Predicting Survival and Metastases in Hepatocellular Carcinoma (miR-207, miR-219, miR-30c,miR-124a) DE EP 07867402.5 Abandoned
NHLBI E-160-2002-0-US-08 Trypotophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins US CON 12/430,023 7923535 Expired PDF
NIMH E-157-2006-1-JP-05 Methods To Identify Patients At Risk Of Developing Adverse Events During Treatment With Antidepressant Medication JP National Stage 2009-534893 Abandoned
NHLBI E-337-2008-0-US-01 Self-expanding Stent For Aortic Valve Replacement US 61/172,568 Abandoned
NIAMS E-116-2005-0-US-03 Tissue Engineered Cartilage, Methods o Making Same, Theuraputics and Cosmetic Surgical Application Using Same US National Stage 11/922,251 8202551 Abandoned PDF
NCI E-140-2006-0-US-02 A Fullerene-based Anticoagulent US National Stage 12/446,967 Abandoned
NCI E-097-2009-0-US-01 Chimeric Mouse/human Anti-human ROR1 MAb 2A2 US 61/172,099 Abandoned